Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS- 103 and activity against (multi)drug resistant cells

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 1, 2000, Pages 78-84

  Minderman, Hans ^a   Wrzosek, Carol ^a   Cao, Shousong ^a   Rustum, Youcef M ^a   Utsugi, Teruhiro ^b   Kobunai, Takashi ^b   Yamada, Yuji ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Drug resistance; Intercalation; Topoisomerase I; Topoisomerase II

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETHIDIUM BROMIDE; GLYCOPROTEIN P; GYRASE INHIBITOR; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN;

AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CATALYSIS; CONTROLLED STUDY; DNA CROSS LINKING; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERCALATION COMPLEX; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; TUMOR XENOGRAFT;

EID: 0033955462     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006747     Document Type: Article

References (27)

1. 1. Chow KC, Ross WE (1987) Topoisomerase specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol 7: 3119
2. 2. Cortes F, Pinero J (1994) Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells. Cancer Chemother Pharmacol 34: 411
3. 3. D'Arpa P, Beardmore C, Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919
4. 4. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y (1990) Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 50: 5919
5. 5. Futscher BW, Abbaszadegan MR, Domann F, Dalton WS (1994) Analysis of MRP-mRNA in mitoxantrone selected, multidrug resistant human tumor cells. Biochem Pharmacol 47(9): 1601
6. 6. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046
7. 7. Greco WR, Park HS, Rustum YM (1990) An application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 50: 5318
8. 8. Heck MMS, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086
9. 9. Hsiang YH, Lihou MG, Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077
10. 10. Holden JA, Rolfson DH, Wittwer CT (1990) Human DNA topoisomerase-II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 29: 2127
11. 11. Husain I, Mohler JL, Seigler HF, Besterman JM (1994) Elevation of topoisomerase-I messenger RNA, protein and catalytic activity in human tumor: demonstration of tumor-type specificity and implications for cancer. Cancer Res 47: 539
12. 12. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50(4): 604
13. 13. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5919
14. 14. Kaufmann SH (1991) Antagonism between camptothecin and topoisomerase-II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129
15. 15. Minderman H, Vanhoefer U, Toth K, Minderman MD, Rustum YM (1996) A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance. Cancer 78(11): 2427
16. 16. Osheroff N (1989) Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 41: 223
17. 17. Potmesil M, Hsiang Y-H, Liu LF, Bank B, Grossberg H, Kirschenbaum S, Forlenzar TJ, Penziner A, Kanganis D, Knowles D, Traganos F, Silber R (1988) Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48: 3537
18. 18. Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. Ann Oncol 8(9): 837
19. 19. Slovak ML, Hoeltge GA, Dalton WS, Trent JM (1988) Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 48: 2793
20. 20. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SPC (1993) Localization of a novel multidrug resistance associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 53: 3221
21. 21. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T (1990) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962
22. 22. Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. JNCI (22): 1732
23. 23. Utsugi T, Aoyagi K, Asao T, Okazaki S, Aoyagi Y, Sano M, Wierzba K, Yamada Y (1997) Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res 88: 992
24. 24. Van der Zee AG, Hollema H, De Jong S, Boonstra H, Gouw A, Willemse PHB, Zijlstra JG, De Vries ECE (1991) P-glycoprotein expression and DNA topoisomerase- and -II activity in malignant tumor of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915
25. 25. Vanhoefer U, Harstrick A, Achterrath W, Kohne CH, Muller C, Kretschmar A, Krauss C, Wilke H, Seeber S (1998) Phase I study of a weekly schedule of irinotecan (CPT-11), high dose folinic acid (FA) and 5-fluorouracil (5-FU) as first line chemotherapy (CT) in metastatic colorectal cancer: Final Results. Proc ASCO (17), 202a
26. 26. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65: 635
27. 27. Woyrianowski JM, Sigmund RD, Beerman TA (1988) Topoisomerase-II mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives VM26 and VP16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA. Biochim Biophys Acta 950: 21